Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06339138 · ClinicalTrials.gov registry record
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
A clinical trial of Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 589
- Enrollment target
- 1
- Study location
NCT06339138 is a study of Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 589 participants, above the 232-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (154% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06339138, a study of Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 589 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 589 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2027-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06339138
The ClinicalTrials.gov registry entry for NCT06339138 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 589 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 232-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (154% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06339138 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06339138 about?
NCT06339138 is a clinical study titled "Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study". This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
What is the current status of trial NCT06339138?
This trial is currently active not recruiting. The enrollment target is 589 participants. The study started on 2018-06-27. Estimated completion is 2027-01-31.
What conditions does trial NCT06339138 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor.
What interventions are being tested in trial NCT06339138?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06339138?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06339138 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.